Hydrochloric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ABL1 ACE ACHE ACVR1 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 AGTR1 ALK AVPR1A AVPR2 BCHE BCR CA2 CACNA1A CACNA1B CACNA1C CACNA1D CACNA1E CACNA1F CACNA1G CACNA1H CACNA1I CACNA1S CACNA2D1 CACNA2D2 CACNA2D3 CACNA2D4 CACNB1 CACNB2 CACNB3 CACNB4 CACNG1 CACNG2 CACNG3 CACNG4 CACNG5 CACNG6 CACNG7 CACNG8 CALCRL CASR CCR5 CDK4 CDK6 CFB CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 CHRNA1 CHRNA3 CHRNA7 CHRNB1 CHRNB4 CHRND CHRNE CHRNG COXFA4 COXFA4L2 CRBN CSF1R CUL4A CYP19A1 DDB1 DPP4 DRD1 DRD2 DRD3 DRD4 EDNRA EGFR EML4 ERBB2 ERBB4 ESR1 ESR2 FGFR1 FGFR3 FLT1 FLT3 FLT4 GAA GABRA1 GABRA2 GABRA3 GABRA4 GABRA5 GABRA6 GABRB1 GABRB2 GABRB3 GABRD GABRE GABRG1 GABRG2 GABRG3 GABRP GABRQ GHSR GLA GNRHR GPD2 GRIN1 GRIN2A GRIN2B GRIN2C GRIN2D GRIN3A GRIN3B GSTP1 HCN4 HCRTR1 HCRTR2 HDAC1 HDAC10 HDAC11 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HRH1 HRH2 HRH3 HSD11B1 HSP90AA1 HSP90AB1 HTR1A HTR1B HTR1D HTR1E HTR1F HTR2A HTR2B HTR2C HTR3A HTR3B HTR3C HTR3D HTR3E HTR4 HTR5A HTR6 HTR7 IMPDH1 IMPDH2 ITGA2B ITGB3 ITK JAK1 JAK2 KCNA1 KCNA10 KCNA2 KCNA3 KCNA4 KCNA5 KCNA6 KCNA7 KCNB1 KCNB2 KCNC1 KCNC2 KCNC3 KCNC4 KCND1 KCND2 KCND3 KCNF1 KCNG1 KCNG2 KCNG3 KCNG4 KCNH1 KCNH2 KCNH3 KCNH4 KCNH5 KCNH6 KCNH7 KCNH8 KCNJ2 KCNJ3 KCNJ5 KCNK3 KCNK9 KCNQ1 KCNQ2 KCNQ3 KCNQ4 KCNQ5 KCNS1 KCNS2 KCNS3 KCNV1 KCNV2 KDR KIT KLKB1 LCK M MAOA MAOB MAPK14 MET MMP1 MMP13 MMP7 MMP8 MT-ND1 MT-ND2 MT-ND3 MT-ND4 MT-ND4L MT-ND5 MT-ND6 NDUFA1 NDUFA10 NDUFA11 NDUFA12 NDUFA13 NDUFA2 NDUFA3 NDUFA5 NDUFA6 NDUFA7 NDUFA8 NDUFA9 NDUFAB1 NDUFAF1 NDUFAF2 NDUFAF3 NDUFAF4 NDUFB1 NDUFB10 NDUFB11 NDUFB2 NDUFB3 NDUFB4 NDUFB5 NDUFB6 NDUFB7 NDUFB8 NDUFB9 NDUFC1 NDUFC2 NDUFS1 NDUFS2 NDUFS3 NDUFS4 NDUFS5 NDUFS6 NDUFS7 NDUFS8 NDUFV1 NDUFV2 NDUFV3 NR3C1 NS5A NTRK1 NTRK2 NTRK3 ODC1 OPRD1 OPRK1 OPRM1 P2RY12 PAH PARP1 PDE3A PDE3B PDE4A PDE4B PDE4C PDE4D PDE5A PDE7A PDE7B PDE8A PDE8B PDGFRA PDGFRB PIK3CA PIK3CD PNP POLA1 POLA2 POLD1 POLD2 POLD3 POLD4 POLE POLE2 POLE3 PPARG PRIM1 PRIM2 PRKCA PRKCB PRKCD PRKCE PRKCG PRKCH PRKCI PRKCQ PRKCZ PRKD1 PRKD3 PTGS1 PTGS2 RBX1 REN RET ROCK1 ROCK2 RPE65 RRM1 RRM2 RRM2B S1PR1 S1PR2 S1PR3 S1PR4 S1PR5 SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SCNN1A SCNN1B SCNN1G SIGMAR1 SLC18A2 SLC6A1 SLC6A2 SLC6A3 SLC6A4 SLC9A3 SRC TACR1 TOP1 TOP2A TOP2B TTR TYMP dacA dacB dacC embA folA ftsI gyrA gyrB mrcA mrcB mrdA parC parE pol rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmG3 rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

	gene	UniProt	supporting neighbours	confidence
▸	HRH3 known ✓	Q9Y5N1	1/20	0.38

▸	SIGMAR1 known ✓	Q99720	1/20	0.33

▸	GNAI3	P08754	1/20	0.37

▸	GNAO1	P09471	1/20	0.37

▸	GNAI1	P63096	1/20	0.37

▸	RAD52	P43351	1/20	0.36

▸	ALOX15	P16050	1/20	0.35

▸	KDM4E	B2RXH2	1/20	0.33

▸	MEN1	O00255	1/20	0.33

▸	USP2	O75604	1/20	0.33

▸	LMNA	P02545	1/20	0.33

▸	MAPT	P10636	1/20	0.33

▸	HPGD	P15428	1/20	0.33

▸	ALOX12	P18054	1/20	0.33

▸	KMT2A	Q03164	1/20	0.33

▸	SMN1; SMN2	Q16637	1/20	0.33

▸	NPSR1	Q6W5P4	1/20	0.33

▸	TDP1	Q9NUW8	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Hydrochloric Acid SCHEMBL28996755	1.00	HRH3 (0.38)	HRH3GNAI3GNAO1GNAI1RAD52
SCHEMBL10552270	0.97	HRH3 (0.39)	HRH3GNAI3GNAO1GNAI1RAD52
SCHEMBL23853043	0.91	HRH3 (0.43)	HRH3GNAI3GNAO1GNAI1ALOX15
SCHEMBL3412350	0.91	—	—
Hydrochloric Acid SCHEMBL29891395	0.88	ALOX15 (0.42)	GNAI3GNAO1GNAI1RAD52ALOX15
SCHEMBL7511785	0.85	ALOX15 (0.44)	HRH3RAD52ALOX15KDM4ESIGMAR1
SCHEMBL11570567	0.85	—	—
Hydrochloric Acid SCHEMBL409216	0.84	PAOX (0.45)	HRH3GNAI3GNAO1GNAI1MEN1
Hydrochloric Acid SCHEMBL374447	0.84	PAOX (0.45)	HRH3GNAI3GNAO1GNAI1MEN1
Hydrochloric Acid SCHEMBL737731	0.83	HRH3 (0.57)	HRH3RAD52LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12624118-B2	Trispecific binding molecules against BCMA and uses thereof	NOVARTIS AG (CH)	2026-05-12	—	—	US	disclosed
WO-2026085795-A1	SILENCED FC REGIONS	PROTEINTECH GROUP, INC. (US)	2026-04-30	—	—	WO	disclosed
US-20260035473-A1	BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view	NOVARTIS AG (CH)	2026-02-05	—	—	US	disclosed
US-20250326855-A1	ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES	GO THERAPEUTICS, INC. (US)	2025-10-23	—	—	US	disclosed
EP-4630456-A1	ANTI-CMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF	Mythic Therapeutics, Inc. (US)	2025-10-15	—	—	EP	disclosed
US-20250304716-A1	ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES	GO THERAPEUTICS, INC. (US)	2025-10-02	—	—	US	disclosed
US-20250223359-A1	CD19 BINDING MOLECULES AND USES THEREOF	NOVARTIS AG (CH)	2025-07-10	—	—	US	disclosed
US-20250136701-A1	ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES	GO THERAPEUTICS, INC. (US)	2025-05-01	—	—	US	disclosed
US-12275795-B2	Binding molecules against BCMA and uses thereof	NOVARTIS AG (CH)	2025-04-15	—	—	US	disclosed
US-12269892-B2	Anti-glyco-MUC1 antibodies and their uses	GO THERAPEUTICS, INC. (US)	2025-04-08	—	—	US	disclosed
US-20050090529-A1	3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation	PFIZER INC	2005-04-28	—	—	US	disclosed
US-20050090509-A1	Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents	Agouron Pharmaceuticals,Inc.	2005-04-28	—	—	US	disclosed
US-20050070508-A1	Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents	AGOURON PHARMACEUTICALS, INC.	2005-03-31	—	—	US	disclosed
WO-2005021554-A1	THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS	PFIZER INC. (US)	2005-03-10	—	—	WO	disclosed
WO-2005021553-A1	NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS	PFIZER INC. (US)	2005-03-10	—	—	WO	disclosed
US-20050026960-A1	3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation	AGOURON PHARMACEUTICALS, INC.	2005-02-03	—	—	US	disclosed
WO-2005009997-A1	3,5 DISUBSTITUTED INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MEDIATING OR INHIBITING CELL PROLIFERATION	PFIZER INC. (US)	2005-02-03	—	—	WO	disclosed
US-20040224988-A1	Dosage forms and methods of treatment using VEGFR inhibitors	AGOURON PHARMACEUTICALS, INC.	2004-11-11	—	—	US	disclosed
WO-2004087152-A1	DOSAGE FORMS COMPRISING AG013736	PFIZER INC. (US)	2004-10-14	—	—	WO	disclosed
US-20040192735-A1	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	AGOURON PHARMACEUTICALS, INC.	2004-09-30	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20050090509-A1	Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents	CCNA1, PGF, CCNA2	HRH3 203/4885SIGMAR1 1615/4885GNAI3 1988/4885
US-12269892-B2	Anti-glyco-MUC1 antibodies and their uses	MUC1, SIGLEC7, SIGLEC9	HRH3 3686/4885SIGMAR1 4741/4885GNAI3 546/4885
US-20250136701-A1	ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES	CD2BP2, CSGALNACT1, DNTT	HRH3 2463/4885SIGMAR1 3729/4885GNAI3 647/4885
US-20040192735-A1	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	CDK3, BRAF, CNKSR1	HRH3 1831/4885SIGMAR1 4829/4885GNAI3 403/4885
US-20050026960-A1	3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation	CDK3, CDK4, CDKL3	HRH3 2564/4885SIGMAR1 4876/4885GNAI3 405/4885
US-20250326855-A1	ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES	CD44, SIGLEC7, SIGLEC9	HRH3 1205/4885SIGMAR1 2783/4885GNAI3 1731/4885
US-20260035473-A1	BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view	BCL9, BRCA1, VCAM1	HRH3 120/4885SIGMAR1 423/4885GNAI3 4848/4885
US-12624118-B2	Trispecific binding molecules against BCMA and uses thereof	CD2, CD40, CD22	HRH3 35/4885SIGMAR1 866/4885GNAI3 4294/4885
US-20050070508-A1	Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents	CCNA1, CCNA2, CCNT1	HRH3 126/4885SIGMAR1 498/4885GNAI3 2265/4885
US-20050090529-A1	3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation	CDK3, CDK4, CDK9	HRH3 2212/4885SIGMAR1 4833/4885GNAI3 435/4885
US-20040224988-A1	Dosage forms and methods of treatment using VEGFR inhibitors	FLT1, FLT4, KDR	HRH3 3457/4885SIGMAR1 1838/4885GNAI3 1796/4885
US-20250223359-A1	CD19 BINDING MOLECULES AND USES THEREOF	CD22, BCL9, CD2	HRH3 1905/4885SIGMAR1 4076/4885GNAI3 1457/4885
US-12275795-B2	Binding molecules against BCMA and uses thereof	EPCAM, CD40, BCR	HRH3 1928/4885SIGMAR1 2977/4885GNAI3 2255/4885
US-20250304716-A1	ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES	MUC1, SIGLEC7, SIGLEC9	HRH3 3686/4885SIGMAR1 4741/4885GNAI3 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.